TFA Therapeutics, Inc 6-K, filed Mar 19, 2024
TFA Therapeutics, Inc. (RAJAF)
About this 6-K
TFA Therapeutics, Inc filed this 6-K on March 19, 2024.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March 2024
Commission File Number: 333-269315
CORDYCEPS SUNSHINE BIOTECH HOLDINGS CO., LTD.
(Translation of registrant’s name into English)
6th Fl.,
No. 15, Lane 548, Ruiguang Road,
Neihu District, Taipei City, Taiwan
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.
Form 20-F ☒ Form 40-F ☐
Changes in Company’s Certifying Accountant.
| (1) | Previous Independent Registered Public Accounting Firm |
| (i) | On March 18, 2024, Cordyceps Sunshine Biotech Holdings Co., Ltd. (the “Company”) notified its independent registered public accounting firm, KCCW Accountancy Corp. its decision to dismiss KCCW Accountancy Corp. as the Company’s auditor. |
| (iii) | The decision to change the independent registered public accounting firm was approved by the Board of Directors of the Company. |
| (iv) | During September 28, 2023 and through March 18, 2024, the date of dismissal, (a) there were no disagreements with KCCW Accountancy Corp. on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of KCCW Accountancy Corp., would have caused it to make reference thereto in its reports on the financial statements for such years and (b) there were no “reportable events” as described in Item 304(a)(1)(v) of Regulation S-K. |
| (v) | On March 18, 2024, the Company provided KCCW Accountancy Corp. with a copy of this Current Report and has requested that it furnish the Company with a letter addressed to the U.S. Securities and Exchange Commission stating whether it agrees with the above statements. A copy of such letter is attached as Exhibit 16.1 to this Report of Foreign Private Issuer on Form 6-K. |
| (2) | New Independent Registered Public Accounting Firm |
On March 18, 2024, the Board of Directors of the Company approved and ratified the appointment of TPS Thayer, LLC as its new independent registered public accounting firm to audit the Company’s financial statements. During the two most recent fiscal years ended December 31, 2023 and 2022 and any subsequent interim periods through the date hereof prior to the engagement of TPS Thayer, LLC, neither the Company, nor someone on its behalf, has consulted TPS Thayer, LLC regarding:
| (i) | either: the application of accounting principles to a specified transaction, either completed or proposed; or the type of audit opinion that might be rendered on the Company’s consolidated financial statements, and either a written report was provided to the Company or oral advice was provided that the new independent registered public accounting firm concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or |
| (ii) | any matter that was either the subject of a disagreement as defined in paragraph 304(a)(1)(iv) of Regulation S-K or a reportable event as described in paragraph 304(a)(1)(v) of Regulation S-K. |
Exhibit Index
| Exhibit No. | Description | |
| 16.1 | Letter from KCCW Accountancy Corp. addressed to the U.S. Securities and Exchange Commission |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Date: March 18, 2024 | CORDYCEPS SUNSHINE BIOTECH HOLDINGS CO., LTD. | |
| By: | /s/ Szu Hao Huang | |
| Name: | Szu Hao Huang | |
| Title: | Director, Chief Executive Officer, | |
| Chief Financial Officer | ||
2
Exhibit 16.1
 |
Audit ● Tax ● Consulting ● Financial Advisory |
| Registered with Public Company Accounting Oversight Board (PCAOB) |
March 18, 2024
Securities and Exchange Commission
Office of the Chief Accountant
100 F Street, NE
Washington, D.C. 20549
Re: Cordyceps Sunshine Biotech Holdings Co., Ltd.
Dear Sir or Madam:
We have read the statements made by Cordyceps Sunshine Biotech Holdings Co., Ltd. of its Form 6-K dated March 18, 2024. We agree with the statements concerning our firm in such Form 6-K; we are not in a position to agree or disagree with other statements of Cordyceps Sunshine Biotech Holdings Co., Ltd. contained therein.
| Very truly yours, | |
| /s/ KCCW Accountancy Corp | |
| Diamond Bar, CA |